Purine-Nucleoside Phosphorylase
"Purine-Nucleoside Phosphorylase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme that catalyzes the reaction between a purine nucleoside and orthophosphate to form a free purine plus ribose-5-phosphate. EC 2.4.2.1.
| Descriptor ID |
D011683
|
| MeSH Number(s) |
D08.811.913.400.725.800
|
| Concept/Terms |
Purine-Nucleoside Phosphorylase- Purine-Nucleoside Phosphorylase
- Phosphorylase, Purine-Nucleoside
- Purine Nucleoside Phosphorylase
- Inosine Phosphorylase
- Phosphorylase, Inosine
- Purine Nucleoside Phosphorylases
- Nucleoside Phosphorylases, Purine
- Phosphorylases, Purine Nucleoside
|
Below are MeSH descriptors whose meaning is more general than "Purine-Nucleoside Phosphorylase".
Below are MeSH descriptors whose meaning is more specific than "Purine-Nucleoside Phosphorylase".
This graph shows the total number of publications written about "Purine-Nucleoside Phosphorylase" by people in this website by year, and whether "Purine-Nucleoside Phosphorylase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Purine-Nucleoside Phosphorylase" by people in Profiles.
-
Metabolites of purine nucleoside phosphorylase (NP) in serum have the potential to delineate pancreatic adenocarcinoma. PLoS One. 2011 Mar 23; 6(3):e17177.
-
Forodesine: review of preclinical and clinical data. Future Oncol. 2010 Aug; 6(8):1211-7.
-
Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood. 2010 Aug 12; 116(6):886-92.
-
Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2006 Oct 01; 108(7):2392-8.
-
A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood. 2005 Dec 15; 106(13):4253-60.
-
Enzymatic properties of the unnatural beta-L-enantiomers of 2',3'-dideoxyadenosine and 2',3'-didehydro-2',3'-dideoxyadenosine. J Med Chem. 1997 Nov 21; 40(24):3969-73.
-
Cytotoxicity, metabolism, and mechanisms of action of 2',2'-difluorodeoxyguanosine in Chinese hamster ovary cells. Cancer Res. 1995 Apr 01; 55(7):1517-24.
-
Purine pathway enzymes in the circulating malignant cells of patients with cutaneous T-cell lymphoma. Br J Haematol. 1982 Sep; 52(1):97-104.
-
Purine pathway enzyme abnormalities in acute lymphoblastic leukemia. Cancer Res. 1981 Nov; 41(11 Pt 2):4821-23.
-
Lymphoblast purine pathway enzymes in B-cell acute lymphoblastic leukemia. Blood. 1981 Aug; 58(2):330-2.